Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces today that it received a medium-term financing of 3 M€, through a bond issue.
This strengthens the cash position of the company at a time when Quantum Genomics is very close to launch its phase II clinical trials of QGC001, first in class drug candidate for the treatment of hypertension
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2014/12/QGC_PR_Financing_20141208_UK.pdf” target=”_blank” title=”Download press release” size=”small” color=”red”]